HK1138602A1 - Sequence based engineering and optimization of single chain antibodies - Google Patents

Sequence based engineering and optimization of single chain antibodies

Info

Publication number
HK1138602A1
HK1138602A1 HK10103877.0A HK10103877A HK1138602A1 HK 1138602 A1 HK1138602 A1 HK 1138602A1 HK 10103877 A HK10103877 A HK 10103877A HK 1138602 A1 HK1138602 A1 HK 1138602A1
Authority
HK
Hong Kong
Prior art keywords
optimization
single chain
chain antibodies
sequence based
based engineering
Prior art date
Application number
HK10103877.0A
Other languages
English (en)
Inventor
David Urech
Leonardo Borras
Original Assignee
Esbatech A Novartis Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech A Novartis Co Llc filed Critical Esbatech A Novartis Co Llc
Publication of HK1138602A1 publication Critical patent/HK1138602A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK10103877.0A 2007-03-12 2010-04-21 Sequence based engineering and optimization of single chain antibodies HK1138602A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90636507P 2007-03-12 2007-03-12
PCT/EP2008/001958 WO2008110348A1 (en) 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies

Publications (1)

Publication Number Publication Date
HK1138602A1 true HK1138602A1 (en) 2010-08-27

Family

ID=39586970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103877.0A HK1138602A1 (en) 2007-03-12 2010-04-21 Sequence based engineering and optimization of single chain antibodies

Country Status (12)

Country Link
US (2) US8280711B2 (he)
EP (2) EP3202786A3 (he)
JP (1) JP5622397B2 (he)
CN (2) CN101668771B (he)
AU (1) AU2008226067B2 (he)
CA (1) CA2680564C (he)
HK (1) HK1138602A1 (he)
IL (1) IL200710A (he)
IN (1) IN2009DN05758A (he)
NZ (1) NZ579594A (he)
RU (2) RU2009137582A (he)
WO (1) WO2008110348A1 (he)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101668771B (zh) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
EP3216803B1 (en) 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
JP6100463B2 (ja) 2008-06-25 2017-03-22 エスバテック − ア ノバルティス カンパニー エルエルシー ＴＮＦαを阻害する安定かつ可溶性の抗体
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
GB201310859D0 (en) * 2013-06-18 2013-07-31 Cambridge Entpr Ltd Rational method for solubilising proteins
JP6580570B2 (ja) * 2013-09-06 2019-09-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体安定性を向上させるための方法
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
MA42821A (fr) 2015-09-15 2018-07-25 Amgen Inc Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CA3043528A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
TWI831762B (zh) 2018-01-12 2024-02-11 美商安進公司 Pac1抗體及其用途
WO2019233984A1 (en) * 2018-06-08 2019-12-12 Ventana Medical Systems, Inc. Universal or normalized antibody frameworks for improved functionality and manufacturability
TW202110877A (zh) 2019-05-30 2021-03-16 美商安進公司 工程改造鉸鏈區以驅動抗體二聚化
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
WO2021102049A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
IL293640A (he) 2019-12-20 2022-08-01 Amgen Inc מבני נוגדן רב-ספציפיים מיועדי-מזותלין אנטגוניסטיים ל-cd40 לטיפול בגידולים מוצקים
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
JP2023544769A (ja) 2020-10-07 2023-10-25 アムジエン・インコーポレーテツド 多重特異性抗体の構築のためのビルディングブロックの合理的選択
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
WO2022190007A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
JP2024515301A (ja) 2021-04-20 2024-04-08 アムジエン・インコーポレーテツド 多重特異性及び一価のｉｇｇ分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
CA3240046A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK0669836T3 (da) * 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994025591A1 (en) * 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
CA2243459C (en) * 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
CN1062312C (zh) * 1996-11-29 2001-02-21 中国科学院微生物研究所 抗ⅳ型胶原酶单链抗体
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0985039B1 (en) * 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
NZ528199A (en) * 1998-08-11 2005-06-24 Idec Pharma Corp Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1140239B1 (en) 1998-12-14 2004-07-14 Osteotech, Inc., Bone graft made of bone particles
CN1232039A (zh) * 1999-04-02 1999-10-20 中国人民解放军海军总医院 一种基因工程双特异抗体及其应用
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
ES2225269T3 (es) * 1999-12-28 2005-03-16 Esbatech Ag Intracuerpos con esqueleto definido que es estable en un ambiente reductor y aplicaciones de los mismos.
BR0015875A (pt) 2000-05-10 2003-06-24 Mayo Foundation Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
CA2453662A1 (en) * 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
CN103739706B (zh) * 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
WO2005051998A2 (en) 2003-11-28 2005-06-09 Astrazeneca Ab Antibodies binding to a c-terminal fragment of apolipoprotein e
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
JP5113523B2 (ja) * 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
WO2006131013A2 (en) 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
EP3366702B1 (en) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
ES2820837T3 (es) 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
CN101668771B (zh) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
SI2158315T1 (sl) * 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화

Also Published As

Publication number Publication date
CN101668771A (zh) 2010-03-10
AU2008226067A1 (en) 2008-09-18
IL200710A (he) 2014-07-31
EP2118138A1 (en) 2009-11-18
NZ579594A (en) 2012-03-30
CN103275216A (zh) 2013-09-04
JP5622397B2 (ja) 2014-11-12
WO2008110348A1 (en) 2008-09-18
IL200710A0 (en) 2010-05-17
CN101668771B (zh) 2013-08-21
US8280711B2 (en) 2012-10-02
CA2680564C (en) 2018-05-01
RU2009137582A (ru) 2011-04-20
AU2008226067B2 (en) 2012-11-08
CA2680564A1 (en) 2008-09-18
IN2009DN05758A (he) 2015-07-24
EP3202786A2 (en) 2017-08-09
CN103275216B (zh) 2015-05-06
US20100137150A1 (en) 2010-06-03
EP3202786A3 (en) 2017-10-11
JP2010523077A (ja) 2010-07-15
RU2014127308A (ru) 2016-02-10
US20130053259A1 (en) 2013-02-28
US9938336B2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
HK1137035A1 (en) Sequence based engineering and optimization of single chain antibodies
HK1138602A1 (en) Sequence based engineering and optimization of single chain antibodies
IL248723B (he) נוגדנים ספציפיים כנגד קומפלקס bcr ושיטות להשתמש בהם
HRP20160684T1 (hr) Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
EP1999470A4 (en) IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
ZA201106118B (en) Anti-vegf antibody compositions and methods
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
HK1194395A1 (zh) 抗體及其製備和使用方法
HK1138329A1 (zh) 包含抗體代理輕鏈序列的構建和文庫
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
IL197937A0 (en) Antibodies to lymphotoxin-alpha
IL231891A0 (he) נוגדנים אנטי–2ephriinb ושיטות לשימוש בהם
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
ZA200902346B (en) Antibodies to lymphotoxin-alpha
PL384339A1 (pl) Wyprażacz łańcuchowy
HUP0600762A2 (en) Delaying chain